Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease

17-Nov-2009 - United Kingdom

Lab901 and Biofortuna announced that they will collaborate on the launch of an automated PCR Dx system for the rapid detection of certain HLA-related diseases such as coeliac disease. Lab901 will be optimising its automated ScreenTape® PCR diagnostics platform for use with Biofortuna’s range of multiplex PCR diagnostics kits for the detection of Coeliac disease, and other HLA related disease such as reactive arthritis, diabetes and drug hypersensitivity.

Dr Mike Bunce, Biofortuna’s CEO said “We are very excited about the launch of our first line of kits for Coeliac disease susceptibility and Abacavir hypersensitivity. Biofortuna’s blend of easy-to-use one-step PCR technology and multiplexing capability means we are confident of quickly taking market share. Having evaluated several automated systems, we have chosen to work with Lab901 because of the ease-of-use, cost-effectiveness and reproducibility of the ScreenTape platform".

Financial terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content

Last viewed contents

Asterion Raises £355k Funding to Progress Novel Therapies for Hormone Related Diseases

Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase

Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery

Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer

Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

Merck and Washington University working on diagnostics and treatment of malnutrition - Genome editing to be used in intestinal bacteria research

Biophage Pharma announces sale of Immunotox Labs Division to Validapro BioSciences Inc